Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07454057

Prospective Observational Study of Exhaled Carbon MonoxideTrajectories and Outcomes in ICU Patients

This is a single-center, prospective, observational study in adult intensive care unit (ICU) patients. The study will measure exhaled carbon monoxide (eCO) once daily for up to 7 days after ICU admission using a red blood cell lifespan breath analyzer, which simultaneously estimates erythrocyte lifespan. eCO is a gas produced endogenously during heme degradation and may reflect hemolysis, oxidative stress, and inflammation in critically ill patients.

The purpose of this study is to describe how eCO changes over time in ICU patients and to determine whether different eCO patterns are associated with clinical outcomes. The primary outcome is all-cause mortality within 28 days after enrollment. Secondary outcomes include 90-day mortality, acute kidney injury, organ dysfunction assessed by SOFA score, transfusion requirement, changes in anemia-related indices, ICU length of stay, and duration of invasive mechanical ventilation. Participation does not change routine clinical care; study procedures involve breath sampling and collection of clinical data from the medical record.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Background: Endogenous carbon monoxide is generated in the human body and may increase during critical illness due to hemolysis, oxidative stress, and inflammation. Whether longitudinal patterns of exhaled carbon monoxide (eCO) provide prognostic information in critically ill patients remains unclear.

Design and setting: This is a single-center, prospective, observational cohort study conducted in an adult intensive care unit (ICU). The study is designed to characterize longitudinal eCO patterns and evaluate their clinical significance in critically ill patients without altering routine clinical management.

Study procedures and data collection: eCO will be measured once daily from Day 0 (baseline, within 24 hours of ICU admission/enrollment) through Day 7 when feasible, using a standardized breath analysis device. For patients receiving mechanical ventilation, breath sampling will be performed according to a standardized protocol for ventilated patients. In addition to serial eCO measurements, demographic characteristics, admission diagnosis, comorbidities, severity-of-illness scores, key treatments, and laboratory variables relevant to hemolysis, inflammation, organ function, anemia, and iron metabolism will be collected from the electronic medical record and protocol-defined assessments, as applicable.

Analytic approach: Group-based trajectory modeling (GBTM) will be used to identify distinct eCO trajectory groups from repeated measurements. Associations between eCO trajectories and prespecified clinical outcomes will be evaluated using Kaplan-Meier methods and multivariable Cox proportional hazards models with adjustment for clinically relevant covariates. Additional exploratory analyses will assess relationships between eCO trajectories and laboratory biomarker patterns, including anemia-related, iron metabolism-related, and inflammatory indices. Machine learning methods (e.g., XGBoost with SHAP-based interpretation) may also be used in exploratory analyses to develop risk prediction models incorporating eCO and other clinical variables.

Study conduct: No intervention is assigned as part of the study, and all treatment decisions remain at the discretion of the treating clinicians.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Admitted to the intensive care unit (ICU) at the study site
  • Expected ICU length of stay ≥ 48 hours
  • Able to complete exhaled carbon monoxide (eCO) measurement (spontaneously breathing or mechanically ventilated)
  • Written informed consent provided by the patient or a legally authorized representative

Exclusion criteria

  • Carbon monoxide poisoning
  • Active smoking within 24 hours prior to ICU admission
  • Unable to perform breath sampling (e.g., massive airway bleeding, severe airway obstruction, extracorporeal membrane oxygenation)
  • Ineffective sampling due to poor mask seal or special ventilation modes
  • Pregnant or breastfeeding
  • Known hereditary hemoglobinopathies (e.g., sickle cell disease, thalassemia)
  • Patient or family refusal
  • Other conditions deemed unsuitable by investigators

Treatment and study plan

Primary outcomes

  1. 28-day all-cause mortality

    Time frame: From enrollment (Day 0) up to Day 28

Secondary outcomes

  1. 90-day all-cause mortality

    Time frame: From enrollment up to Day 90

  2. Acute kidney injury (AKI) (KDIGO)

    Time frame: From enrollment through ICU discharge (up to 28 days)

    Incidence and staging of acute kidney injury defined by KDIGO 2012 criteria (serum creatinine increase ≥0.3 mg/dL within 48 hours, or ≥1.5 times baseline within 7 days, or urine output <0.5 mL/kg/h for ≥6 hours) during ICU hospitalization.

  3. Organ dysfunction assessed by SOFA score

    Time frame: Daily from Day 0 (baseline) through Day 7

    Daily Sequential Organ Failure Assessment (SOFA) score, a composite organ dysfunction scale ranging from 0 to 24, encompassing respiratory, coagulation, liver, cardiovascular, neurological, and renal subsystems. Each of the 6 organ system components is scored from 0 to 4, with higher scores indicating worse organ dysfunction and greater illness severity. Scores will be assessed daily from Day 0 (baseline) through Day 7.

  4. Red blood cell transfusion requirement

    Time frame: Up to 28 days after ICU admission/enrollment

    Whether red blood cell transfusion was administered (yes/no), number of transfusion episodes, and total units transfused within 28 days after ICU admission.

  5. ICU length of stay

    Time frame: From ICU admission to ICU discharge (up to 90 days)

    Total duration of invasive mechanical ventilation during the ICU stay.

  6. Duration of invasive mechanical ventilation

    Time frame: From enrollment to liberation from invasive mechanical ventilation or ICU discharge (up to 28 days)

    Total duration of invasive mechanical ventilation during the ICU stay.

  7. Complete blood count-related panel

    Time frame: Up to 28 days after enrollment

    Longitudinal changes in complete blood count-related indices, including hemoglobin, reticulocyte count, and red cell distribution width (RDW), and their associations with eCO trajectories.

  8. Changes in iron metabolism related indices

    Time frame: Baseline and up to 28 days after enrollment

    Longitudinal changes in iron metabolism- and erythropoietin-related indices, including serum iron, ferritin, transferrin saturation, soluble transferrin receptor, and erythropoietin (EPO), and their associations with eCO trajectories.

Other outcomes

  1. Exploratory mortality risk prediction model

    Time frame: From enrollment up to Day 28

    Machine learning-based mortality risk prediction model (XGBoost) incorporating eCO trajectories and clinical variables, with variable importance assessed by SHAP values. This is an exploratory analysis evaluated by 5-fold cross-validation.

Study contacts

Contact information is provided by the study sponsor or research team.

Fei Leng, MD.

CONTACT

[email protected]

021-64041990

Hongyu He

CONTACT

[email protected]

021-64041990

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

Prospective Observational Study of Exhaled Carbon Monoxide Trajectories and Outcomes in ICU Patients

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 6, 2026
Registry last updated
Mar 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.